TY - JOUR
T1 - Etanercept in spondyloarthropathies. Part I
T2 - Current evidence of efficacy
AU - Palazzi, C.
AU - D'Angelo, S.
AU - Cantini, F.
AU - Lubrano, E.
AU - Marchesoni, A.
AU - Mathieu, A.
AU - Salvarani, C.
AU - Scarpa, R.
AU - Spadaro, A.
AU - Olivieri, I.
PY - 2011
Y1 - 2011
N2 - Etanercept is a recombinant soluble tumour necrosis factor alpha receptor administered subcutaneously at the dose of 50 mg weekly (or 25 mgltwice weekly) for the treatment of the main chronic arthritides: rheumatoid arthritis and spondyloarthropathies. It shows high qualities in terms of efficacy and manageability. Favourable results were reported in all localisations of spondyloarthropathies: axial disease, peripheral arthritis, and enthesitis. In particular, several studies demonstrated its efficacy on the clinical and functional indicators of ankylosing spondylitis. Similar data were also reported for psoriatic arthritis in which, in addition, a significant reduction in the progression of erosive damages was widely described. Furthermore, although only a few studies are available, very interesting results have been obtained in patients suffering from undifferentiated spondyloarthropathies and severe enthesitis.
AB - Etanercept is a recombinant soluble tumour necrosis factor alpha receptor administered subcutaneously at the dose of 50 mg weekly (or 25 mgltwice weekly) for the treatment of the main chronic arthritides: rheumatoid arthritis and spondyloarthropathies. It shows high qualities in terms of efficacy and manageability. Favourable results were reported in all localisations of spondyloarthropathies: axial disease, peripheral arthritis, and enthesitis. In particular, several studies demonstrated its efficacy on the clinical and functional indicators of ankylosing spondylitis. Similar data were also reported for psoriatic arthritis in which, in addition, a significant reduction in the progression of erosive damages was widely described. Furthermore, although only a few studies are available, very interesting results have been obtained in patients suffering from undifferentiated spondyloarthropathies and severe enthesitis.
KW - Ankylosing spondylitis
KW - Efficacy
KW - Etanercept
KW - Psoriatic arthritis
KW - Spondiloarthropathies
UR - http://www.scopus.com/inward/record.url?scp=83455173656&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=83455173656&partnerID=8YFLogxK
M3 - Article
C2 - 22041180
AN - SCOPUS:83455173656
VL - 29
SP - 858
EP - 864
JO - Clinical and Experimental Rheumatology
JF - Clinical and Experimental Rheumatology
SN - 0392-856X
IS - 5
ER -